

UVA Startups that received Proof-Concept Funding from:
Coulter Translational Partnerships, Ivy Biomedical Innovation Fund,
LaunchPad for Diabetes



Advaray, Inc. (formerly BrachyFoam, LLC) is currently engaged in the preclinical development of a hydrogel-based device to improve methods of image-guided pelvic brachytherapy. Their products will be inspired by unmet clinical needs in image-guided brachytherapy and designed to improve patient care from the perspectives of both patients and their physicians. Advaray's core technologies resulted from collaborations between UVA and Virginia Tech faculty.

<https://www.advaray.com/>

The logo for AMP3D is displayed in white, italicized, serif font against a dark blue rectangular background.

Advanced Medical Predictive Devices, Diagnostics And Displays, Inc. (AMP3D) has developed a platform for analytics and displays that makes sense of "Big Data" in health care. AMP3D at a glance enables earlier intervention and better outcomes by predicting potentially catastrophic events like emergent intubation, hemorrhage, and severe sepsis that can quadruple mortality and increase lengths-of-stay by more 9 days on average. AMP3D will use demonstrable return-on-investment to sell its platform as a service on a value-based pricing basis, aimed directly at quality measures and performance standards that impact reimbursement and payment. A 20% reduction in emergent intubations at a single medical ICU, for example, can save \$600,000 annually; the addressable overall market opportunity for the in-patient market alone is in the billions of dollars.

<https://amp3d.biz/>

The logo for Cerillo features the word "cerillo" in a blue, lowercase, sans-serif font. A small orange flame-like shape is positioned above the letter 'i'.

Cerillo designs and develops highly functional laboratory tools so that researchers can focus on research. The Stratus is the company's flagship product, which is a portable plate reader that measures optical density outputs in real-time for applications that include bacterial growth and protein quantitation.

<https://cerillo.bio/>

contraline

Contraline, a male contraceptive company has created a polymer solution called Echo-V that he hopes will finally lead to contraceptive equality.

Echo-V is a patent-pending, ultrasound-visible polymer solution that is injected into the vas deferens. It forms a hydrogel device that acts as a semi-permeable membrane, blocking sperm while allowing fluids through. You can think of it like a male version of an IUD, or an IVD (intra-vas device). The device does not affect hormones in any way

<http://www.contraline.com/>



CytoRecovery is bringing to market advanced microfluidic technology to enable cell biologists and other life science researchers to rapidly select and recover rare, homogeneous, viable cell subpopulations from tissue, blood and other biological samples. We are working to empower your laboratory with new cell separation capabilities for cell biology research. Our technology is unique in its ability to recover populations of specific cells based upon their biophysical properties in a sterile environment and without impacting the cells, enabling their maintenance and viability for further analysis and use in biomedical research. As the technology does not use cell markers, cells are recovered in their native, unbiased state, and previously undetected rare cell populations can be recovered – a powerful tool for advancing our new understanding of the tumor microenvironment. This company is a result of a collaboration with UVA and Virginia Tech.

<https://cytorecovery.com/>



EpiEP, Inc. is a medical device company that has developed an FDA cleared and CE marked epicardial access system, EpiAccess™. This system engages a patent protected pressure-guided needle that is designed to alert physicians of needle tip location during epicardial access procedures. Entering the pericardial space with a minimally invasive technique is considered the “final frontier” for electrophysiology procedures. EpiEP has devoted itself to developing a specialized instrument that will facilitate an epicardial approach for patients who will benefit from minimally invasive procedures on the surface of the heart.

<https://www.epiep.com/>



Everactive formerly PsiKick, Inc. is a deep technology company whose origins stretch back over a decade to the pioneering ultra-low-power circuit research of our co-founders at the Massachusetts Institute of Technology. Upon receiving their doctorates, each took teaching positions at their respective alma maters—the University of Virginia and the University of Michigan. After several years of incubation and several groundbreaking proof points, the technology was licensed out of those two universities; Everactive was born.

The core circuit design and wireless communication IP has served as the building block for Everactive's self-powered, batteryless systems. The company has since added all of the requisite pieces—cloud software, data analytics, systems expertise, and industrial design—to develop a complete end-to-end sensing solution. Now, with the technology fully commercialized, Everactive continues to innovate with a suite of industrial sensing products focused on delivering critical insights that are simply not possible with battery-powered devices.

<https://everactive.com>



GenEp is a biotech company that focusses on targeting genetic epilepsies. They have developed small molecules that target CNS expressed sodium channels for the treatment of genetic epilepsy such as SCN8A and SCN2A epileptic encephalopathy and treatment of therapy resistant temporal lobe epilepsy.



GID BIO, Inc. is a global leader in cellular therapy, offering a tissue processing platform that enables cell-based treatments for a broad range of therapies. Our team of seasoned executives, adipose tissue scientists and surgeons works together to discover reliable, cost-effective solutions that utilize patients' own cells as a treatment option.

<https://gidbio.com>



HemoShear Therapeutics is a clinical stage company developing new treatments for patients with rare metabolic disorders. We apply our deep understanding of complex diseases to discover breakthrough treatments for our proprietary pipeline. We also partner with biopharma companies to accelerate their drug discovery and development programs in liver diseases, gout and metabolic disorders. We are implementing a new vision for how advanced biological systems can yield new insights that improve health and quality of life for patients in need.

<https://hemoshear.com/>



HemoSonics is a medical device company developing a point-of-care diagnostic platform to guide the management of critical bleeding to improve outcomes and reduce healthcare costs by enabling more targeted transfusion of blood products. The Quantra Hemostasis Analyzer is designed to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely information on coagulation status at the point of care. HemoSonics is headquartered in Charlottesville, VA, with research, development and manufacturing facilities in Durham, NC. They were acquired by the Stago Group in 2017

<https://hemosonics.com/>



KeViRx is an early stage drug discovery company whose mission is to advance new anticancer therapeutics to clinical testing. We focus on novel molecular targets for cancer. Our current lead candidate, KVX-053, is an allosteric PTP4A3 phosphatase small molecule inhibitor that has potent activity in cell-based models of ovarian cancer and leukemia.

Our goal is to discover safer and more effective drugs that enable people to live longer and to live well.

<http://www.kevirx.com/>



PS Fertility takes the approach that next generation fertility testing starts with HIM

Our novel discovery of PS factor and its role in fertilization take fertility testing to a level beyond sperm counting and motility measurement. Our advanced testing platform will measure and analyze male fertility levels based upon our proprietary biomarker. PS Fertility will be a CLIA certified lab and will offer initially offer 2 male fertility diagnostic tests

<https://psfertility.com/>



RetiVue LLC is focused on providing novel, high definition retinal imaging technology with a wider field of view to help document early eye disease to help needless blindness. The RetiVue WF Desktop and RetiVue WF Portable are the first affordable non-mydratic widefield retina cameras for everyone from babies to adults.

Our revolutionary design allows you to image up to ten times more of the retina than competing devices. Point and shoot automatic image capture gives you perfect images of the eye every time, regardless of level of expertise. Our company strives to become the de-facto standard equipment used for eye screening, capturing higher quality images, while simultaneously maintaining device affordability and simplifying ease of use.

<https://www.retivue.com>



RIVANNA is a privately held designer, manufacturer, and distributor of medical technologies and services based in Charlottesville, VA and holds more than 25 patents protecting ultrasound-based innovations. The Company operates an FDA registered and ISO 13485:2016 certified manufacturing facility where it produces the Accuro® product line and related medical equipment and components.

RIVANNA offers its select group of industry partners with a number of services that include clinical support, product repair and replacement, in addition to regulatory, contract design, and contract manufacturing services.

<https://rivannamedical.com>



Slate Bio an immunotherapeutics development company creating therapies that restore the body's natural immunological response in various diseases using bifunctional IL233 cytokine, thereby providing users with a second independent synergistic pathway that has greater tissue selectivity and improved pharmacodynamics, at lower doses and without side-effects. Currently under development is an interleukin 2 fusion cytokine for the potential treatment of autoimmune and inflammatory diseases.

<https://slatebio.com>



Springbok Analytics' AI-powered software solutions provide the most accurate, rapid and comprehensive insight and analysis of the human musculoskeletal system available in the world, replacing current inferior methods and furthering the transformation to precision medicine and personalized health. Our solutions offer significant value in a wide range of clinical applications, including injury prevention, injury recovery, performance enhancement, and the treatment of musculoskeletal conditions. Since our founding in 2013, Springbok Analytics has adhered to the original vision: we seek to revolutionize how the world views human muscle.

www.springbokanalytics.com



SoundPipe is medical device startup company that has developed the Penello platform as an intravascular ultrasound system that uses a catheter mounted ultrasound device to improve drug delivery. This will allow interventionalists to deliver antiproliferative drugs to the diseased vessel safely. Currently under development, our patented technology will revolutionize the treatment of CLI.

<http://www.sound-pipe.com/>



Syntrillo formerly Neuroview, we're re-imagining neurological care. Through a combination of digital health and AI, we are making expert-level, preventative stroke care accessible to the millions of people at-risk of stroke.

Stroke is the leading cause of long-term disability worldwide, but it doesn't have to be this way. We know that with the right kind of care, 8 out of 10 strokes could be prevented.

<https://syntrillo.com>



TearSolutions is focused on dry eye, the most common eye disease. The mission of TearSolutions is to advance a novel tear generation therapy for dry eye through Phase II human clinical trials. The platform technology is centered on the remarkable tear protein lacritin that was discovered by the founders while at the University of Virginia. TearSolutions has developed a proprietary synthetic fragment of lacritin called Lacripep. Lacripep is water soluble, stable in human tears for 16 hr, and equipotent to lacritin in cell protection studies.

<https://tearsolutions.com/>



TypeZero Technologies, LLC / DexCom, Inc., is leveraging more than 10 years of clinical trials, research, and innovation to develop the inControl Diabetes Management Platform to improve and simplify the lives of people with diabetes. In 2018, the company was acquired by DexCom, Inc., a publicly traded company, headquartered in San Diego, Calif., and the leader in continuous glucose monitoring for people with diabetes. TypeZero's headquarters will remain in Charlottesville with its current team of 15 employees, and expects to expand its operations and team in Virginia over the new few years.

<https://www.dexcom.com/>



ZielBio is an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes. Our proprietary drug discovery platform Zielfind™ combines the power of functional, high throughput screening with large content data analytics to identify high value targets. We have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind™.

www.zielbio.com

Add:

Neuroview Health

Vasarya

Companies no longer active

NeoAntigenics Ovastasis Syphx

??? UNSURE

TeGrex/MicroGem